Acadia Pharmaceuticals reported $108.67M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
ALKERMES USD 298.96M 37.75M Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Cara Therapeutics USD 900K 0 Mar/2025
Corcept Therapeutics USD 13.18M 295K Jun/2026
Cytokinetics USD 380K 226K Jun/2026
Eisai JPY 257.55B 21.09B Mar/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Incyte USD 112.54M 3.08M Jun/2026
J&J USD 15.14B 561M Jun/2026
Moderna USD 280M 134M Jun/2026
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026